Screener
Jazz Pharmaceuticals JAZZ Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total assets | $11,859.6 | $11,659.3 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $100.0 | $122.1 |
| Accrued liabilities | 1,022.4 | 1,034.2 |
| Current portion of long-term debt | 1,030.5 | 1,029.9 |
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's accounts payable?
- Jazz Pharmaceuticals (JAZZ) reported accounts payable of $100M in Q1 2026.
- How has Jazz Pharmaceuticals's accounts payable changed year-over-year?
- Jazz Pharmaceuticals's accounts payable increased by 4.2% year-over-year, from $95.93M to $100M.
- What is the long-term trend for Jazz Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's accounts payable has grown at a 35.3% compound annual growth rate (CAGR), from $26.95M to $122.1M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Jazz Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude